CombiGene is part of “Sweden to become a world leader in development and implementation of advanced therapies by 2030”,
CombiGene is part of project called “Sweden to become a world leader in development and implementation of advanced therapies by 2030”, which is a part of the Swedish innovation agency Vinnova’s venture “Vision Driven Health”. The project, which was recently approved, is coordinated by Research Institutes of Sweden (RISE) and consists of 15 partners from healthcare, industry, public authorities, academia and institutes – there among, as mentioned, CombiGene.
Read the press release here.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.